Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant tislelizumab plus platinum-doublet chemotherapy in resectable NSCLC
ChiCTR2200062945Phase 2Not yet recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Second Hospital of Lanzhou University. Primary endpoints: Pathologic complete response rate and Major pathologic response rate. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200062945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062945.